Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Novo Nordisk A/S ... rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Novo Nordisk has started building ... up 3% on the same period of 2023 - but Novo Nordisk has a stated ambition of generating a "sustained growth outlook" for the business as sales of some ...

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million - Following pre-NDA meeting with FDA, on track to submit TransCon CNP ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Growth hormone injections can be administered in children with growth disorders at any convenient time for the family as ...

Both growth rates are at constant exchange rates. The results, unfortunately, weren't enough to lift shares of Novo Nordisk much higher, as investors likely weren't thrilled with the slowing ...

Novo Nordisk reported, this month, that full-year sales of all its drugs grew 26% to $40.5 billion. However, the company projects that sales growth in 2025 will slow down to between 16% and 24%.